• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Conformis launches Image-to-Implant Platinum Services program, provides financial update

Conformis launches Image-to-Implant Platinum Services program, provides financial update

January 6, 2022 By Sean Whooley

ConformisConformis (NSDQ:CFMS) today provided a business update introducing its new Image-to-Implant Platinum Services program to investors.

Billerica, Massachusetts–based Conformis aims for its new Image-to-Implant Platinum Services program to allow patients to upgrade to a fully-personalized Identity knee system by paying an incremental deluxe services fee.

According to a news release, the company’s program, new to orthopedics, seeks to address the demands of the healthcare market whereby patients are increasingly willing to pay a premium for personalized treatment offerings. Conformis said the approach enables participating medical facilities to establish and offer patients an out-of-pocket upgrade to obtain the Identity knee system.

Conformis will roll out the program to its existing customer base by Sept. 1, 2022.

“Although new to orthopedics, this concept is not new to healthcare,” Conformis President & CEO Mark Augusti said in the news release. “We believe this will create an expanded market for personalized orthopedic services and continue to enhance our value proposition to the surgeons and patients we serve.”

Conformis also confirmed that it expects to report product revenue of approximately $15.3 million for the fourth quarter of 2021, falling just in line with its guidance of between $15 million and $17 million, set on Nov. 3, 2021.

The company expects full-year 2022 product revenue to grow into a range of $60 million to $70 million but does not expect to provide formal updates to its annual expectations range during the year because of COVID-19 causing elective procedures unpredictability.

Shares of CFMS were slightly up, rising 1% at 74¢ per share by midday trading today. The company announced earlier this week that it is currently not in compliance with the minimum bid price requirement ($1 per share) for continued Nasdaq listing and could eventually face delisting from the market.

“Conformis is positioned well as we head into 2022. We are seeing traction with our new Imprint knee system, and we are excited about the introduction of the Platinum Services Program, which is a first in orthopedics and builds on our rich history of pioneering and developing patient-specific solutions,” Augusti said.

“This new program will enable surgeons and patients to select their preferred therapy together; whether it be Imprint, which is our new standardized knee implant system, or Identity, which is our premium fully-personalized total knee system that now offers patients a five-year limited warranty, underscoring our commitment to design excellence, manufacturing quality, and patient satisfaction.”

Filed Under: Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, News Well, Orthopedics, Wall Street Beat Tagged With: conformis

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy